BR9915946B1 - formulaÇço de vacina para a administraÇço nasal compreendendo antÍgeno de superfÍcie do vÍrus da hepatite b (hbsag) e antÍgeno de nucleocapsÍdeo viral. - Google Patents
formulaÇço de vacina para a administraÇço nasal compreendendo antÍgeno de superfÍcie do vÍrus da hepatite b (hbsag) e antÍgeno de nucleocapsÍdeo viral.Info
- Publication number
- BR9915946B1 BR9915946B1 BRPI9915946-5A BR9915946A BR9915946B1 BR 9915946 B1 BR9915946 B1 BR 9915946B1 BR 9915946 A BR9915946 A BR 9915946A BR 9915946 B1 BR9915946 B1 BR 9915946B1
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- hbsag
- hepatitis
- nasal administration
- vaccine formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU1998183A CU22871A1 (es) | 1998-12-02 | 1998-12-02 | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal |
PCT/CU1999/000006 WO2000032229A1 (es) | 1998-12-02 | 1999-12-01 | Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal |
Publications (2)
Publication Number | Publication Date |
---|---|
BR9915946A BR9915946A (pt) | 2001-08-21 |
BR9915946B1 true BR9915946B1 (pt) | 2010-12-14 |
Family
ID=5459504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI9915946-5A BR9915946B1 (pt) | 1998-12-02 | 1999-12-01 | formulaÇço de vacina para a administraÇço nasal compreendendo antÍgeno de superfÍcie do vÍrus da hepatite b (hbsag) e antÍgeno de nucleocapsÍdeo viral. |
Country Status (13)
Country | Link |
---|---|
US (1) | US7374766B1 (pt) |
EP (1) | EP1136077B1 (pt) |
CN (1) | CN1191853C (pt) |
AR (1) | AR021414A1 (pt) |
AT (1) | ATE331528T1 (pt) |
BR (1) | BR9915946B1 (pt) |
CA (1) | CA2352777C (pt) |
CU (1) | CU22871A1 (pt) |
DE (1) | DE69932182T2 (pt) |
ES (1) | ES2264273T3 (pt) |
HK (1) | HK1042424B (pt) |
PT (1) | PT1136077E (pt) |
WO (1) | WO2000032229A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0031079D0 (en) * | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Vaccine |
CU23031A1 (es) * | 2002-01-24 | 2005-02-23 | Ct Ingenieria Genetica Biotech | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes |
US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
AU2003277448A1 (en) * | 2002-10-17 | 2004-05-04 | Enzo Therapeutics, Inc. | Transmucosal administration of aggregated antigens |
CU23405A1 (es) * | 2003-10-20 | 2009-08-04 | Ct Ingenieria Genetica Biotech | Composiciones farmacéuticas para uso terapéutico |
EP1764369A1 (de) | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Hbv 백신 및 그의 제조 방법 |
EP3344293A4 (en) * | 2015-09-04 | 2019-01-16 | Inventprise, LLC. | STABILIZED VACCINE COMPOSITIONS OF VLP |
KR20200038339A (ko) | 2015-09-10 | 2020-04-10 | 인벤트프라이즈 엘엘씨 | 다가 vlp 접합체 |
ES2965709T3 (es) | 2016-03-31 | 2024-04-16 | Ct Ingenieria Genetica Biotecnologia | Composición farmacéutica que incluye los antígenos de superficie y nucleocápside del virus de la hepatitis B |
TWI634899B (zh) * | 2016-11-22 | 2018-09-11 | 國立臺灣大學 | 包含類b肝病毒顆粒作為佐劑的疫苗組成物 |
EP3804752A4 (en) * | 2018-06-05 | 2022-03-09 | Toko Yakuhin Kogyo Co., Ltd. | TRANSNASAL DELIVERY SYSTEM FOR HEPATITIS B VACCINE |
CN111450245A (zh) * | 2020-04-29 | 2020-07-28 | 艾棣维欣(苏州)生物制药有限公司 | 一种乙型肝炎治疗疫苗及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4547368A (en) * | 1983-12-20 | 1985-10-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Hepatitis B core antigen vaccine made by recombinant DNA |
US4882145A (en) * | 1986-12-09 | 1989-11-21 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US6319501B1 (en) * | 1990-07-19 | 2001-11-20 | Health Research, Inc. | Method of immunizing against hepatitis B virus |
US5840303A (en) | 1991-08-26 | 1998-11-24 | The Scripps Research Foundation | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
US5780036A (en) * | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
HUT68510A (en) | 1991-08-26 | 1995-06-28 | Cytel Corp | Process for producing hla-restricted hapatitis b virus ctl epitopes and pharmaceutical compositions containing them |
EP0642355B1 (en) * | 1992-05-23 | 1998-07-15 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Combined vaccines comprising hepatitis b surface antigen and other antigens |
US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
WO1994012617A1 (en) * | 1992-11-25 | 1994-06-09 | International Biotechnology Laboratories, Inc. | Hepatitis b virus vaccines |
US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
GB9419979D0 (en) * | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
US5962428A (en) * | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
FR2732605B1 (fr) | 1995-04-07 | 1997-05-16 | Pasteur Merieux Serums Vacc | Composition destinee a l'induction d'une reponse immunitaire mucosale |
RU2189254C2 (ru) * | 1995-06-06 | 2002-09-20 | Америкэн Хоум Продактс Корпорэйшн | Вакцины против вирусов гепатита |
US6153392A (en) | 1997-07-30 | 2000-11-28 | Bionova Corporation | Devices and methods comprising an HBcAg from hepatitis B virus |
ATE333501T1 (de) | 1997-09-05 | 2006-08-15 | Medimmune Inc | Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps) |
US6436402B1 (en) | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
-
1998
- 1998-12-02 CU CU1998183A patent/CU22871A1/es unknown
-
1999
- 1999-11-26 AR ARP990106037 patent/AR021414A1/es not_active Application Discontinuation
- 1999-12-01 WO PCT/CU1999/000006 patent/WO2000032229A1/es active IP Right Grant
- 1999-12-01 CN CNB998151912A patent/CN1191853C/zh not_active Expired - Lifetime
- 1999-12-01 DE DE1999632182 patent/DE69932182T2/de not_active Expired - Lifetime
- 1999-12-01 US US09/857,402 patent/US7374766B1/en not_active Expired - Fee Related
- 1999-12-01 CA CA 2352777 patent/CA2352777C/en not_active Expired - Fee Related
- 1999-12-01 BR BRPI9915946-5A patent/BR9915946B1/pt not_active IP Right Cessation
- 1999-12-01 AT AT99957844T patent/ATE331528T1/de not_active IP Right Cessation
- 1999-12-01 ES ES99957844T patent/ES2264273T3/es not_active Expired - Lifetime
- 1999-12-01 EP EP19990957844 patent/EP1136077B1/en not_active Expired - Lifetime
- 1999-12-01 PT PT99957844T patent/PT1136077E/pt unknown
-
2002
- 2002-02-22 HK HK02101388.6A patent/HK1042424B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1191853C (zh) | 2005-03-09 |
ATE331528T1 (de) | 2006-07-15 |
HK1042424B (zh) | 2007-05-11 |
DE69932182D1 (de) | 2006-08-10 |
EP1136077B1 (en) | 2006-06-28 |
BR9915946A (pt) | 2001-08-21 |
EP1136077A1 (en) | 2001-09-26 |
CA2352777C (en) | 2009-09-08 |
HK1042424A1 (en) | 2002-08-16 |
ES2264273T3 (es) | 2006-12-16 |
DE69932182T2 (de) | 2007-05-10 |
US7374766B1 (en) | 2008-05-20 |
WO2000032229A1 (es) | 2000-06-08 |
CN1332637A (zh) | 2002-01-23 |
PT1136077E (pt) | 2006-10-31 |
AR021414A1 (es) | 2002-07-17 |
CU22871A1 (es) | 2003-10-21 |
CA2352777A1 (en) | 2000-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9915946B1 (pt) | formulaÇço de vacina para a administraÇço nasal compreendendo antÍgeno de superfÍcie do vÍrus da hepatite b (hbsag) e antÍgeno de nucleocapsÍdeo viral. | |
GC0000202A (en) | Combined vaccine composition comprising a hepatitis b viral (hbv) antigen and a human papillomavirus(hpv) antigen | |
NL300365I1 (nl) | Recombinante influenzavirussen voor vaccins en gentherapie | |
EP0595436A3 (en) | Swine virus, pathogen of the multiplying respiratory disease, vaccines and its viral DNA. | |
GB9912254D0 (en) | Viral replication detection using a counter virus | |
ATE376825T1 (de) | Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung | |
ATE275631T1 (de) | Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff | |
EE05442B1 (et) | Vikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks | |
FI963717A (fi) | Uusia mutatoituja viruksia, viruksenvastaisia yhdisteitä ja uusia menetelmiä rokotteiden valmistamiseksi | |
GC0000201A (en) | Combined vaccine composition comprising a herpes simplex virus (hsv) antigen and a human papillomavirus (hpv) antigen | |
NO20091761L (no) | Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav | |
LU91327I2 (fr) | Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé) | |
MX9603896A (es) | Vacuna para la prevencion de enfermedades respiratorias y reproductivas del cerdo, que contiene virus parainfluenza. | |
DE60040727D1 (de) | Menschliche papillomavirus impfstoff-formulierungen | |
PL360096A1 (en) | Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine | |
DE69839169D1 (de) | Aus infektiöser cDNA gewonnene rekombinate YF Viren-Impfstoffe | |
NZ288254A (en) | Method, including an ultracentrifugation step, for preparing an influenza virus, antigens obtained and applications thereof | |
FR2728794B1 (fr) | Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro | |
AU4932601A (en) | Recombinant parainfluenza virus expression systems and vaccines | |
DZ1706A1 (fr) | Vaccin contre le virus de l'hepatite a. | |
AU2001246331A1 (en) | Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof | |
DE4192786T1 (de) | Masernvirus-Rekombinanter Pockenvirus-Impfstoff | |
IL147605A0 (en) | Mosaic infectious bursal disease virus vaccines | |
EP1749885B8 (en) | Infectious and attenuated bovine viral diarrhea virus vaccine | |
IL131212A0 (en) | Recombinant virus and live-virus vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/12/2010, OBSERVADAS AS CONDICOES LEGAIS. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 20A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |